Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Vertex presented interim data at NACFC showing ALYFTREK restored exocrine pancreatic function in some children ages 2-5, with 37.5% of the 48-child substudy successfully discontinuing pancreatic enzyme replacement therapy. Mean fecal elastase-1 rose 110.2 µg/g from baseline to 239.7 µg/g, with nearly half of children reaching the sufficiency threshold — challenging the long-held view that pancreatic failure in CF is irreversible.
Key figures
- Drug Name
- ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor)
- Phase Of Trial
- Phase 3 open-label extension
- Substudy n
- 48
- Full cohort n
- 66
- Mean fe1 ug g
- 239.7
- Pert discontinued pct
- 37.5%
- Pct reaching sufficiency threshold
- 48.6%
- Mean fe1 increase from baseline ug g
- 110.2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.